期刊文献+

清化消瘀方对Ⅱ型糖尿病合并高脂血症患者糖氧化修饰过程的影响 被引量:8

EFFECTS OF QINGHUAXIAOYU PRESCRIPTION ON GLYCOSYLATED AND OXIDIZED MODIFIED PROCESS OF PATIENTS WITH DIABETICS ⅡCOMBINED HYPERLIPIDEMIA
下载PDF
导出
摘要 目的 :观察清化消瘀方对Ⅱ型糖尿病合并高脂血症患者糖氧化修饰过程的影响。方法 :72例Ⅱ型糖尿病合并高血脂症患者随机分为两组 ,对照组予西药常规治疗方案 (但禁用抗氧化剂 ) ,治疗组在对照组基础上加用清化消瘀方 ,疗程 4周 ,治疗前后测定血浆Gly -LDL、Ox -LDL、Gly -Ox -LDL。结果 :治疗组、对照组治疗前与正常对照组比较血浆Gly -LDL、Ox -LDL、Gly-Ox -LDL均明显升高 (P <0 0 1) ,而治疗后治疗组Gly -LDL、Ox -LDL、Gly-Ox -LDL均明显降低 (P <0 0 1) ,与正常对照组比较差异无显著性意义(P >0 0 5 )。结论 :Ⅱ型糖尿病合并高脂血症患者由于糖化修饰过程 ,导致晚糖化终产物含量增高 ,清化消瘀方能阻断这一进程 。 Objective:To observe the effect of qinghuaxiaoyu prescripition on glycosylated and oxidized modified process in type Ⅱ diabetics combined hyperlipidemia.Methods:72 patients were randomly divided into two groups including qinghuxiaoyu treated group and western medicine control group.The level of Gly-LDL、Ox-LDL、Gly-Ox-LDL in plasma of patients were tested simultaneously before and after treatment.Results:The level of Gly-LDL、Ox-LDL、Gly-Ox-LDL in plasma of patients were significantly higher than those in normal group.After treated with qinghuxiaoyu prescription the level of Gly-LDL、Ox-LDL、Gly-Ox-LDL in plasma of patients were significantly lower than those in control group.Conclusion:qinghuxiaoyu could repress the glycosylated and oxidized modified process in patients with type Ⅱ diabetics combined hyperlipidemia.
出处 《中国中医药科技》 CAS 2004年第6期325-326,共2页 Chinese Journal of Traditional Medical Science and Technology
基金 广东省中医药管理局科研基金项目No.10 1111
  • 相关文献

参考文献5

二级参考文献27

  • 1[9]Hangaishi M, Taguchi J, Miyata T, et al.Biochem Biophys Res Commun, 1998; 248(2): 285~292
  • 2[10]Ichikawa K, Yoshinari M, Iwase M, et al.Atherosclerosis, 1998; 136(2): 281~287
  • 3[11]Zoukourian C, Wautier MP, Chappey O, et al.Int Angiol, 1996; 15(3): 195~200
  • 4[12]Panagiotopoulos S, O'Brien RC, Bucala R,Atheroosclerosis, 1998; 136(1): 125~ 131
  • 5[13]Kunt T, Forst T, Wilhelm A, et al. Clin Sci Colch, 1999; 96(1): 75~82
  • 6[1]Miyata T, van Ypersele de Strihou C,Kurokawa K, et al. Kidney Int, 1999; 55(2): 389~399
  • 7[2]Nicholl ID, Bucala R. Cell Mol Biol Noisy le grand, 1998; 44(7): 1025~1033
  • 8[3]Sakata N, Meng J, Jimi S, et al. Nippon Ronen Igakkai Zasshi, 1995; 32(5): 336~343
  • 9[4]Huijberts MS, Wolffenbuttel BH, Boudier HA,et al. J Clin Invest, 1993; 92(3): 1407~1411
  • 10[5]Giardino I, Edelstein D, Brownlee M, et al. J Clin Invest, 1996; 97(6): 1422~1428

共引文献32

同被引文献52

引证文献8

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部